Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Consensus Rating of “Buy” from Brokerages

Cellebrite DI Ltd. (NASDAQ:CLBT) has earned an average recommendation of “Buy” from the five research firms that are presently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have covered the stock in the last year is $22.40.

CLBT has been the subject of a number of recent analyst reports. Lake Street Capital lowered their price target on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, August 15th. JPMorgan Chase & Co. lowered their price target on Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, May 12th. Needham & Company LLC decreased their target price on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, August 14th. Finally, Wall Street Zen raised Cellebrite DI from a “hold” rating to a “buy” rating in a research report on Saturday.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $15.80 on Wednesday. The firm has a market capitalization of $3.78 billion, a price-to-earnings ratio of -20.79, a P/E/G ratio of 3.20 and a beta of 1.27. Cellebrite DI has a 52-week low of $13.10 and a 52-week high of $26.30. The stock has a fifty day moving average of $14.96 and a 200 day moving average of $17.67.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. During the same quarter last year, the company earned $0.10 earnings per share. The firm’s quarterly revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts forecast that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Trading of Cellebrite DI

Several hedge funds and other institutional investors have recently made changes to their positions in CLBT. Bosun Asset Management LLC boosted its stake in shares of Cellebrite DI by 1.4% in the 4th quarter. Bosun Asset Management LLC now owns 43,307 shares of the company’s stock worth $954,000 after buying an additional 584 shares during the last quarter. OneDigital Investment Advisors LLC boosted its stake in shares of Cellebrite DI by 2.5% in the 1st quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company’s stock worth $556,000 after buying an additional 688 shares during the last quarter. Signaturefd LLC boosted its stake in shares of Cellebrite DI by 68.3% in the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after buying an additional 819 shares during the last quarter. TD Waterhouse Canada Inc. boosted its stake in shares of Cellebrite DI by 1.8% in the 4th quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company’s stock worth $1,046,000 after buying an additional 859 shares during the last quarter. Finally, SkyView Investment Advisors LLC boosted its stake in shares of Cellebrite DI by 2.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after buying an additional 970 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.